13th February 2014
The Nanotechnology Knowledge Transfer Network (NanoKTN – www.nanoktn.com), one of the UK’s primary knowledge-based networks for Micro and Nanotechnologies, is pleased to announce the foundation of a new start-up company, NanoScientium, resulting from a NanoKTN NanoPharm focus group meeting held last year at the Stevenage Bioscience Catalyst (SBC).
The NanoKTN NanoPharm focus group meeting - Adoption of Nanotechnology Pharma: Pathways to Commercialise Nanomedicines – was held in February 2013 and brought together relevant pharma industry experts, regulators and academics, to scope out a plan that would serve to catalyse an increase in the number of nanomedicine projects in the UK.
Dr Felicity Sartain, Founder and Director of NanoScientium, comments “One of the key aspects that arose from the meeting was that there is a lot of information and data openly available in this space, thus significant value would be brought to this community if this information could be harnessed and translated to specific company needs. Consequently, with support provided by both Stevenage Bioscience Catalyst and the NanoKTN, we set up NanoScientium to provide comprehensive analysis of technical, clinical and market information for those investing capital or resources into nanomedicines, nanosimilars or medical devices.”
Martino Picardo, CEO of Stevenage Bioscience Catalyst, said "Both SBC and NanoScientium share a common interest and ambition to explore opportunities in the big data and convergent medical technologies area; we see each other as excellent partners.”
NanoScientium provides evidence based assessments of nanotechnologies to determine their potential as nanomedicines. By doing this, NanoScientium enables route to market strategies, including clinical and regulatory pathways, illustrates technology or company positions in the competitive landscape, and values their markets.
Dr Alec Reader, Director at the NanoKTN, added, “The global nanomedicine market is anticipated to grow to $130.9 billion by 2016 and we believe that NanoScientium’s provision of evidence-based assessments of nanomedicines by senior experts in the field, will positively impact the way that investors, and the public in general, look at these new disruptive technologies. We look forward to seeing the future success of NanoScientium and are delighted to have played a part in its foundation.”
For more information about NanoScientium and its services, please visit
www.nanoscientium.com or contact email@example.com.
For further information about the NanoKTN, please visit www.nanoktn.com or email
Established by the Technology Strategy Board, the NanoKTN is managed by Centre for Process Innovation Ltd, a leading technology development and consulting company.
The NanoKTN facilitates the transfer of knowledge and experience between industry and research, offering companies dealing in small-scale technology access to information on new processes, patents and funding as well as keeping up-to-date with industry regulation. The four broad areas that the NanoKTN focuses on are: Promoting and facilitating knowledge exchange, supporting the growth of UK capabilities, raising awareness of Nanotechnology, and providing thought leadership and input to UK policy and strategy.
About The Technology Strategy Board:
The Technology Strategy Board is the UK’s innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit ww.innovateuk.org.
About Knowledge Transfer Networks (KTNs):
KTNs https://ktn.innovateuk.org/web/guest/networks have been set up by government, industry and academia to facilitate the transfer of knowledge and experience between industry and the science base. They bring together diverse organisations and provide activities and initiatives that promote the exchange of knowledge and the stimulation of innovation in these communities.
The first KTNs were set up in 2005 and the network continues to grow. They are active in sectors, technologies and market-based areas and they interact strongly with the government’s Technology Programme and overall technology strategy.
The Centre for Process Innovation (CPI) is a UK based technology innovation centre and part of the government’s High Value Manufacturing Catapult. CPI offers market and technology expertise along with cutting-edge development assets to help its public and private sector clients build and prototype the next generation of products, processes and services quickly and efficiently, and with minimal risk. CPI has the capability to develop products and processes for companies working in the pharma, chemical, energy, transportation and printable electronics markets. Cutting-edge facilities are manned by commercially experienced scientists and engineers, and are equipped with development laboratories, prototyping facilities and pilot plants that enable clients to prove and scale up processes from the laboratory stage through to commercial reality. CPI also offers a multi-disciplined team who work together on project management, investment and market opportunities to ensure each business fulfils its potential.
Fiona Brewer/Graham Thatcher
T: 023 8011 1977
F: 023 8011 1978
Copyright © 2023 Stevenage Bioscience Catalyst